Interlaboratory comparability - an important criterion for selection of a method for relative quntification of BCR-ABL

Abstract

A BCR-ABL fusion transcript found in peripheral blood or bone marrow is a specific molecular marker of chronic myeloid leukemia and Philadelphia chromosome - positive acute lymphoblastic leukemia. The goal of the study is to compare the diagnostic impact of two used systems for BCR-ABL quantification with respect to recommendations of the Europe Against Cancer Program (EAC) unifying the used BCR-ABL methodology.

The principal difference between the tested procedures is the house-keeping gene used for normalization of BCR-ABL quantity. In agreement with the Europe Against Cancer strategy we have selected ABL gene as a normalization gene for our lab.